Intellectual Property India Publishes Patent Application for Design, Synthesis, Characterization, And Biological Evaluation Of Novel Schiff Base–fused 1,2,3-Triazole Scaffolds

MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202641096088 A) filed by Madavi Ramesh, Research Scholar Department Of Chemistry, Satavahana University, Karimnagar.; Dr. Prasad Pinnoju, Assistant Professor Department Of Chemistry, Jntuh University College Of Engineering, Mahabubabad.; Dr. M. Sarasija, Assistant Professor Department Of Chemistry, Satavahana University, Karimnagar.; and Prof. U. Umesh Kumar, Senior Professor Department Of Chemistry on August 08, 2026, for Design, Synthesis, Characterization, And Biological Evaluation Of Novel Schiff Base–fused 1,2,3-Triazole Scaffolds.

Inventors include Madavi Ramesh, Research Scholar Department Of Chemistry; Dr. Prasad Pinnoju, Assistant Professor Department Of Chemistry; Dr. M. Sarasija, Assistant Professor Department Of Chemistry; and Prof. U. Umesh Kumar, Senior Professor Department Of Chemistry.

The application for the patent was published on August 14, 2026, under issue no. 33/2026.

Abstract: Abstract A novel series of Schiff base-fused 1,2,3-triazole hybrid compounds (6a-6l) is disclosed, synthesized via a four-step sequence comprising Schiff base condensation, O-alkylation, azidation, and copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. The synthesized compounds were evaluated for in vitro antibacterial activity against Gram-positive and Gram-negative bacterial strains by the agar streak dilution method, and for in vitro anticancer activity against MCF-7 and HeLa cell lines by the MTT assay, using doxorubicin as the reference drug. Compounds 6i and 6j exhibited the most potent antibacterial activity, while compounds 6d, 6i, and 6j exhibited superior anticancer activity relative to the reference drug. Molecular docking studies against the VEGFR2 crystal structure (PDB ID: 4ASD) revealed favourable binding interactions for the active compounds, exceeding the binding affinity of doxorubicin, thereby supporting their potential as VEGFR2-targeted antibacterial and anticancer agents.

Disclaimer: Curated by HT Syndication.